' 
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8
USERS' SCORE
Good
Based on 1 Review
8.1
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
N-Acetyl-D-Glucosamine
700 mg
†
Top Medical Research Studies
8
NAG enhances asthma drug delivery
Triggering effect of N-acetylglucosamine on retarded drug release from a lectin-anchored chitosan nanoparticles-in-microparticles system.
Contextual relevance to asthma treatment
We explored how N-acetylglucosamine (NAG) can help improve drug delivery in treating asthma. The study involved creating a unique system where a drug called salmeterol xinafoate (SalX) is loaded into nanoparticles and modified with a specific protein called wheat germ agglutinin (WGA). This combination aimed to see if the addition of NAG would enhance drug release from the delivery system.
Our findings revealed that the use of WGA indeed slowed down the initial release of the drug. When NAG was introduced to this modified system, we observed a significant increase in drug release, suggesting that the interaction between NAG and WGA played a vital role. However, it’s important to note that NAG did not have a noticeable effect on drug release from systems that didn’t involve WGA.
This research indicates that NAG could act as a trigger, potentially allowing for better control over how medications are delivered when using lectin-modified carriers. This exciting approach could pave the way for more effective asthma treatments, particularly for those needing tailored therapies at specific times.
Our findings revealed that the use of WGA indeed slowed down the initial release of the drug. When NAG was introduced to this modified system, we observed a significant increase in drug release, suggesting that the interaction between NAG and WGA played a vital role. However, it’s important to note that NAG did not have a noticeable effect on drug release from systems that didn’t involve WGA.
This research indicates that NAG could act as a trigger, potentially allowing for better control over how medications are delivered when using lectin-modified carriers. This exciting approach could pave the way for more effective asthma treatments, particularly for those needing tailored therapies at specific times.
Read More
8
N-Acetylglucosamine in asthma treatment
Sulfated L-selectin ligands as a therapeutic target in chronic inflammation.
Moderate relevance due to focus
We aimed to understand how n-acetylglucosamine (GlcNAc) might help alleviate asthma symptoms. Our research highlighted that the homing of lymphocytes to lymph nodes is intricately linked with the interaction between L-selectin on these cells and a substance called peripheral node addressin (PNAd). The connection relies on specific sulfated sugars, primarily an N-acetylglucosamine derivative.
Particularly, two crucial enzymes, GlcNAc6ST-1 and GlcNAc6ST-2, play a vital role in creating the sugar structure that allows L-selectin to recognize and bind effectively to PNAd. Interestingly, these same sulfotransferases are involved in forming functional PNAd at areas of chronic inflammation, including asthma.
In our findings using a sheep model of asthma, we observed that targeting PNAd did show promise in reducing asthma symptoms, indicating a potential therapeutic approach. However, it's essential to note that while targeting these components is a step forward, the direct effects of isolated n-acetylglucosamine on asthma symptoms specifically were not the focal point of our research.
Particularly, two crucial enzymes, GlcNAc6ST-1 and GlcNAc6ST-2, play a vital role in creating the sugar structure that allows L-selectin to recognize and bind effectively to PNAd. Interestingly, these same sulfotransferases are involved in forming functional PNAd at areas of chronic inflammation, including asthma.
In our findings using a sheep model of asthma, we observed that targeting PNAd did show promise in reducing asthma symptoms, indicating a potential therapeutic approach. However, it's essential to note that while targeting these components is a step forward, the direct effects of isolated n-acetylglucosamine on asthma symptoms specifically were not the focal point of our research.
Read More
Most Useful Reviews
3.8
Asthma symptoms returned
While using this supplement for joint pain, I began to experience asthma symptoms not felt since childhood, even while on oral steroids for another condition. I've stopped using it, but if the asthma improves, I might consider resuming.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8
- All Researches
8
NAG enhances asthma drug delivery
Triggering effect of N-acetylglucosamine on retarded drug release from a lectin-anchored chitosan nanoparticles-in-microparticles system.
Contextual relevance to asthma treatment
We explored how N-acetylglucosamine (NAG) can help improve drug delivery in treating asthma. The study involved creating a unique system where a drug called salmeterol xinafoate (SalX) is loaded into nanoparticles and modified with a specific protein called wheat germ agglutinin (WGA). This combination aimed to see if the addition of NAG would enhance drug release from the delivery system.
Our findings revealed that the use of WGA indeed slowed down the initial release of the drug. When NAG was introduced to this modified system, we observed a significant increase in drug release, suggesting that the interaction between NAG and WGA played a vital role. However, it’s important to note that NAG did not have a noticeable effect on drug release from systems that didn’t involve WGA.
This research indicates that NAG could act as a trigger, potentially allowing for better control over how medications are delivered when using lectin-modified carriers. This exciting approach could pave the way for more effective asthma treatments, particularly for those needing tailored therapies at specific times.
Our findings revealed that the use of WGA indeed slowed down the initial release of the drug. When NAG was introduced to this modified system, we observed a significant increase in drug release, suggesting that the interaction between NAG and WGA played a vital role. However, it’s important to note that NAG did not have a noticeable effect on drug release from systems that didn’t involve WGA.
This research indicates that NAG could act as a trigger, potentially allowing for better control over how medications are delivered when using lectin-modified carriers. This exciting approach could pave the way for more effective asthma treatments, particularly for those needing tailored therapies at specific times.
Read More
8
N-Acetylglucosamine in asthma treatment
Sulfated L-selectin ligands as a therapeutic target in chronic inflammation.
Moderate relevance due to focus
We aimed to understand how n-acetylglucosamine (GlcNAc) might help alleviate asthma symptoms. Our research highlighted that the homing of lymphocytes to lymph nodes is intricately linked with the interaction between L-selectin on these cells and a substance called peripheral node addressin (PNAd). The connection relies on specific sulfated sugars, primarily an N-acetylglucosamine derivative.
Particularly, two crucial enzymes, GlcNAc6ST-1 and GlcNAc6ST-2, play a vital role in creating the sugar structure that allows L-selectin to recognize and bind effectively to PNAd. Interestingly, these same sulfotransferases are involved in forming functional PNAd at areas of chronic inflammation, including asthma.
In our findings using a sheep model of asthma, we observed that targeting PNAd did show promise in reducing asthma symptoms, indicating a potential therapeutic approach. However, it's essential to note that while targeting these components is a step forward, the direct effects of isolated n-acetylglucosamine on asthma symptoms specifically were not the focal point of our research.
Particularly, two crucial enzymes, GlcNAc6ST-1 and GlcNAc6ST-2, play a vital role in creating the sugar structure that allows L-selectin to recognize and bind effectively to PNAd. Interestingly, these same sulfotransferases are involved in forming functional PNAd at areas of chronic inflammation, including asthma.
In our findings using a sheep model of asthma, we observed that targeting PNAd did show promise in reducing asthma symptoms, indicating a potential therapeutic approach. However, it's essential to note that while targeting these components is a step forward, the direct effects of isolated n-acetylglucosamine on asthma symptoms specifically were not the focal point of our research.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
3.8
Asthma symptoms returned
While using this supplement for joint pain, I began to experience asthma symptoms not felt since childhood, even while on oral steroids for another condition. I've stopped using it, but if the asthma improves, I might consider resuming.
